Oxurion NV (ENXTBR: OXUR)
Health Care · Biotechnology · BE
€0.00
+7.69% today · -88.8% 1Y
Oxurion NV (ENXTBR: OXUR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $289.91K and employs 26 people.
Over the last twelve months the share price has lost 88.8%, trading between 0.00 and 0.03.
Tweenvest scores Oxurion NV across four factors: quality 10/100, value 59/100, growth 0/100. Its strongest factor is value.
OXUR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $289.91K
- Revenue (TTM)
- $651.64K
- P/E
- —
- EPS
- -0.13
- Dividend yield
- —
- Beta (5Y)
- -0.11
- 52-week high
- €0.03
- 52-week low
- €0.00
- Avg volume (3M)
- —
- Shares outstanding
- 88.69M
- Employees
- 26
- Next earnings
- —
About Oxurion NV
Headquartered in Leuven, Belgium, and established in 1991, Oxurion N.V. is a biopharmaceutical firm focused on researching, developing, and bringing to market treatments for various ocular conditions worldwide. Its primary commercialized offering is JETREA, a medication used to address vitreomacular adhesion and vitreomacular traction. The company's development pipeline includes THR-149, a plasma kallikrein inhibitor currently undergoing Phase II clinical trials for diabetic macular edema (DME), and THR-687, an integrin antagonist also in Phase II trials for DME. Oxurion has forged strategic partnerships with Bicycle Therapeutics, INC Research, and Galapagos NV. The organization was formerly known as ThromboGenics NV before officially changing its name to Oxurion NV in September 2018.
- ISIN
- BE0974487192
- Founded
- 1991
- Listed since
- Jul 7, 2006
- Exchange
- Euronext Brussels
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.